Abstract
Interferon (IFN) is an effective agent in the treatment of chronic viral hepatitis C. A variety of adverse neuropsychiatric effects including anxiety, depression, delirium, psychoses, and mania complicates its usage. IFN-α-induced depression is presumed to be composed of two overlapping syndromes: a depression-specific syndrome characterized by depressed mood, anxiety, and cognitive complaints, and a neurovegetative syndrome consisting of fatigue, anorexia, somatic pain complaints, and psychomotor retardation [1]. Our results show that depression-specific symptoms peak at 12 weeks of IFN therapy and respond well to serotoninergic antidepressants [2]. We conclude that neurovegetative symptoms are relatively treatment refractory to antidepressants, occur early in the course of treatment, and tend to persist for the duration of therapy [1].
Similar content being viewed by others
References
Raison CL, Demetrashvili M, Capuron L, Miller AH (2005) Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19(2):105–123
Hauser P (2004) Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. Gastroenterol Clin North Am 33(Suppl 1):S35–S50
Geppert CM, Dettmer E, Jakiche A (2005) Ethical challenges in the care of persons with hepatitis C infection: a pilot study to enhance informed consent with veterans. Psychosomatics 46(5):392–401
Poynard T, Cacoub P, Ratziu V, et al. (2002) Fatigue in patients with chronic hepatitis C. J Viral Hepat 9(4):295–303
Sarhill N, Walsh D, Nelson, et al. (2001) Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 18(3):187–192
Krupp LB (2003) Fatigue in multiple sclerosis: definition, pathophysiology and treatment. CNS Drugs 17(4):225–234
Rammohan KW, Rosenberg JH, Lynn DJ, et al. (2002) Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72(2):179–183
Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ (1994) The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 21(1):9–14
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–1123
Alves G, Wentzel-Larsen T, Larsen JP (2004) Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 63(10):1908–1911
Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J (2003) Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 18(3):287– 293
Robertson Jr P, Hellriegel ET (2003) Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 42(2):123– 137
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors have no conflict of interest or financial involvement with this manuscript.
Rights and permissions
About this article
Cite this article
Martin, K.A., Krahn, L.E., Balan, V. et al. Modafinil’s Use in Combating Interferon-Induced Fatigue. Dig Dis Sci 52, 893–896 (2007). https://doi.org/10.1007/s10620-006-9519-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9519-0